Do analysts rate LTRN or TIL?

Instil Bio has a consensus target price of $7.00, indicating a potential upside of 13.27%. Given Instil Bio's stronger consensus rating and higher possible upside, analysts clearly believe Instil Bio is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Instil Bio 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has stronger valuation & earnings, LTRN or TIL?

Instil Bio is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.62 N/A Instil Bio N/A N/A -$71.37M -$4.47 N/A

Is LTRN or TIL more profitable?

Instil Bio's return on equity of -26.78% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -368.02% -148.62% Instil Bio N/A -26.78% -14.89%

Do analysts rate HOWL or LTRN?

Werewolf Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 303.59%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Werewolf Therapeutics is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Werewolf Therapeutics 1 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.43 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is HOWL or LTRN more profitable?

Werewolf Therapeutics' return on equity of -166.99% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Werewolf Therapeutics N/A -166.99% -59.88% Lantern Pharma N/A -368.02% -148.62%

Does the media prefer HOWL or LTRN?

In the previous week, Lantern Pharma had 2 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 5 mentions for Lantern Pharma and 3 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.20 beat Lantern Pharma's score of 0.93 indicating that Werewolf Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Werewolf Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantern Pharma 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate LTRN or TVGN?

Tevogen Bio has a consensus target price of $100.00, indicating a potential upside of 1,306.47%. Given Tevogen Bio's stronger consensus rating and higher probable upside, analysts clearly believe Tevogen Bio is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Tevogen Bio 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation and earnings, LTRN or TVGN?

Tevogen Bio is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.62 N/A Tevogen Bio N/A N/A -$26.27M -$4.63 N/A

Is LTRN or TVGN more profitable?

Tevogen Bio's return on equity of 0.00% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -368.02% -148.62% Tevogen Bio N/A N/A -468.32%

Does the media refer more to LTRN or TVGN?

In the previous week, Lantern Pharma had 2 more articles in the media than Tevogen Bio. MarketBeat recorded 5 mentions for Lantern Pharma and 3 mentions for Tevogen Bio. Lantern Pharma's average media sentiment score of 0.93 beat Tevogen Bio's score of 0.45 indicating that Lantern Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantern Pharma 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tevogen Bio 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer MGX or LTRN?

Metagenomi currently has a consensus target price of $6.00, suggesting a potential upside of 554.09%. Given Metagenomi's stronger consensus rating and higher probable upside, equities research analysts plainly believe Metagenomi is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.75 Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MGX or LTRN more profitable?

Lantern Pharma has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat Lantern Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Metagenomi -384.61% -63.65% -44.52% Lantern Pharma N/A -368.02% -148.62%

Does the media prefer MGX or LTRN?

In the previous week, Lantern Pharma had 3 more articles in the media than Metagenomi. MarketBeat recorded 5 mentions for Lantern Pharma and 2 mentions for Metagenomi. Lantern Pharma's average media sentiment score of 0.93 beat Metagenomi's score of 0.91 indicating that Lantern Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantern Pharma 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend LTRN or EDSA?

Edesa Biotech has a consensus price target of $5.00, indicating a potential upside of 75.44%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Edesa Biotech is more favorable than Lantern Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Edesa Biotech 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.67

Which has higher valuation & earnings, LTRN or EDSA?

Edesa Biotech is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantern Pharma N/A N/A -$17.12M -$1.62 N/A Edesa Biotech N/A N/A -$7.19M -$1.69 N/A

Is LTRN or EDSA more profitable?

Lantern Pharma's return on equity of -368.02% beat Edesa Biotech's return on equity. Company Net Margins Return on Equity Return on Assets Lantern Pharma N/A -368.02% -148.62% Edesa Biotech N/A -560.22% -105.74%

Lantern Pharma (LTRN) Competitors

$0.71 -0.03 (-3.57%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$0.72 +0.01 (+2.01%)

As of 10/13/2026 07:30 PM Eastern

Compare

LTRN vs. TIL, HOWL, TVGN, MGX, and EDSA

Should you buy Lantern Pharma stock or one of its competitors? Lantern Pharma's main competitors and comparable companies include Instil Bio (TIL), Werewolf Therapeutics (HOWL), Tevogen Bio (TVGN), Metagenomi (MGX), and Edesa Biotech (EDSA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lantern Pharma compare to Instil Bio?

Lantern Pharma (NASDAQ:LTRN) and Instil Bio (NASDAQ:TIL) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, valuation, analyst recommendations, media sentiment, profitability and earnings.

In the previous week, Lantern Pharma had 4 more articles in the media than Instil Bio. MarketBeat recorded 5 mentions for Lantern Pharma and 1 mentions for Instil Bio. Instil Bio's average media sentiment score of 1.79 beat Lantern Pharma's score of 0.93 indicating that Instil Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Lantern Pharma	Positive
Instil Bio	Very Positive

Lantern Pharma has a beta of 2.33, indicating that its stock price is 133% more volatile than the broader market. Comparatively, Instil Bio has a beta of 1.94, indicating that its stock price is 94% more volatile than the broader market.

Instil Bio is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Instil Bio	N/A	N/A	-$71.37M	-$4.47	N/A

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 60.6% of Instil Bio shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by insiders. Comparatively, 47.0% of Instil Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Instil Bio's return on equity of -26.78% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Instil Bio	N/A	-26.78%	-14.89%

Instil Bio has a consensus target price of $7.00, indicating a potential upside of 13.27%. Given Instil Bio's stronger consensus rating and higher possible upside, analysts clearly believe Instil Bio is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Instil Bio	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Instil Bio beats Lantern Pharma on 7 of the 12 factors compared between the two stocks.

How does Lantern Pharma compare to Werewolf Therapeutics?

Werewolf Therapeutics (NASDAQ:HOWL) and Lantern Pharma (NASDAQ:LTRN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and media sentiment.

Werewolf Therapeutics' return on equity of -166.99% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Werewolf Therapeutics	N/A	-166.99%	-59.88%
Lantern Pharma	N/A	-368.02%	-148.62%

Lantern Pharma has lower revenue, but higher earnings than Werewolf Therapeutics. Werewolf Therapeutics is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Werewolf Therapeutics	$1.88M	25.62	-$60.82M	-$0.76	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A

Werewolf Therapeutics has a beta of 0.51, meaning that its share price is 49% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.33, meaning that its share price is 133% more volatile than the broader market.

Werewolf Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 303.59%. Given Werewolf Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Werewolf Therapeutics is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Werewolf Therapeutics	1 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.43
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

64.8% of Werewolf Therapeutics shares are held by institutional investors. Comparatively, 28.6% of Lantern Pharma shares are held by institutional investors. 23.6% of Werewolf Therapeutics shares are held by insiders. Comparatively, 8.5% of Lantern Pharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Lantern Pharma had 2 more articles in the media than Werewolf Therapeutics. MarketBeat recorded 5 mentions for Lantern Pharma and 3 mentions for Werewolf Therapeutics. Werewolf Therapeutics' average media sentiment score of 1.20 beat Lantern Pharma's score of 0.93 indicating that Werewolf Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Werewolf Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantern Pharma	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Werewolf Therapeutics beats Lantern Pharma on 11 of the 15 factors compared between the two stocks.

How does Lantern Pharma compare to Tevogen Bio?

Lantern Pharma (NASDAQ:LTRN) and Tevogen Bio (NASDAQ:TVGN) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, dividends, analyst recommendations, profitability, media sentiment and earnings.

In the previous week, Lantern Pharma had 2 more articles in the media than Tevogen Bio. MarketBeat recorded 5 mentions for Lantern Pharma and 3 mentions for Tevogen Bio. Lantern Pharma's average media sentiment score of 0.93 beat Tevogen Bio's score of 0.45 indicating that Lantern Pharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantern Pharma	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tevogen Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

28.6% of Lantern Pharma shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by company insiders. Comparatively, 65.6% of Tevogen Bio shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tevogen Bio's return on equity of 0.00% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Tevogen Bio	N/A	N/A	-468.32%

Tevogen Bio is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Tevogen Bio	N/A	N/A	-$26.27M	-$4.63	N/A

Tevogen Bio has a consensus target price of $100.00, indicating a potential upside of 1,306.47%. Given Tevogen Bio's stronger consensus rating and higher probable upside, analysts clearly believe Tevogen Bio is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Tevogen Bio	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Lantern Pharma has a beta of 2.33, suggesting that its share price is 133% more volatile than the broader market. Comparatively, Tevogen Bio has a beta of 0.19, suggesting that its share price is 81% less volatile than the broader market.

Summary

Lantern Pharma beats Tevogen Bio on 7 of the 11 factors compared between the two stocks.

How does Lantern Pharma compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and Lantern Pharma (NASDAQ:LTRN) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

Metagenomi currently has a consensus target price of $6.00, suggesting a potential upside of 554.09%. Given Metagenomi's stronger consensus rating and higher probable upside, equities research analysts plainly believe Metagenomi is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.75
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lantern Pharma has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -63.65% beat Lantern Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-63.65%	-44.52%
Lantern Pharma	N/A	-368.02%	-148.62%

Lantern Pharma has lower revenue, but higher earnings than Metagenomi. Lantern Pharma is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.37	-$87.87M	-$2.49	N/A
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A

In the previous week, Lantern Pharma had 3 more articles in the media than Metagenomi. MarketBeat recorded 5 mentions for Lantern Pharma and 2 mentions for Metagenomi. Lantern Pharma's average media sentiment score of 0.93 beat Metagenomi's score of 0.91 indicating that Lantern Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Metagenomi	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantern Pharma	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Metagenomi has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Lantern Pharma has a beta of 2.33, indicating that its share price is 133% more volatile than the broader market.

28.6% of Lantern Pharma shares are held by institutional investors. 12.5% of Metagenomi shares are held by company insiders. Comparatively, 8.5% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Metagenomi beats Lantern Pharma on 8 of the 15 factors compared between the two stocks.

How does Lantern Pharma compare to Edesa Biotech?

Lantern Pharma (NASDAQ:LTRN) and Edesa Biotech (NASDAQ:EDSA) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, media sentiment, institutional ownership, risk, profitability, analyst recommendations and dividends.

Lantern Pharma has a beta of 2.33, meaning that its share price is 133% more volatile than the broader market. Comparatively, Edesa Biotech has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market.

Edesa Biotech is trading at a lower price-to-earnings ratio than Lantern Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Edesa Biotech	N/A	N/A	-$7.19M	-$1.69	N/A

Lantern Pharma's return on equity of -368.02% beat Edesa Biotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Edesa Biotech	N/A	-560.22%	-105.74%

28.6% of Lantern Pharma shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 8.5% of Lantern Pharma shares are owned by insiders. Comparatively, 24.4% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Edesa Biotech has a consensus price target of $5.00, indicating a potential upside of 75.44%. Given Edesa Biotech's stronger consensus rating and higher possible upside, analysts clearly believe Edesa Biotech is more favorable than Lantern Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Edesa Biotech	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.67

In the previous week, Lantern Pharma had 4 more articles in the media than Edesa Biotech. MarketBeat recorded 5 mentions for Lantern Pharma and 1 mentions for Edesa Biotech. Edesa Biotech's average media sentiment score of 1.79 beat Lantern Pharma's score of 0.93 indicating that Edesa Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Lantern Pharma	Positive
Edesa Biotech	Very Positive

Summary

Edesa Biotech beats Lantern Pharma on 8 of the 13 factors compared between the two stocks.

Get Lantern Pharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LTRN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LTRN vs. The Competition

Export

Metric	Lantern Pharma	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$11.01M	$3.93B	$7.27B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-0.44	10.78	202.90	19.69
Price / Sales	N/A	1,146.43	561.48	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	1.23	16.70	10.61	6.03
Net Income	-$17.12M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-21.90%	-4.43%	-2.89%	-2.34%
1 Month Performance	-58.44%	-12.49%	-7.37%	-5.31%
1 Year Performance	-83.74%	7.63%	3.00%	-2.94%

Lantern Pharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LTRN Lantern Pharma	0.9308 of 5 stars	$0.71 -3.6%	N/A	-83.9%	$11.01M	N/A	N/A	16
TIL Instil Bio	1.6968 of 5 stars	$6.89 -0.9%	$7.00 +1.6%	-69.7%	$47.13M	N/A	N/A	410
HOWL Werewolf Therapeutics	2.6793 of 5 stars	$0.92 -0.9%	$4.00 +333.8%	-39.2%	$45.20M	$1.88M	N/A	14	News Coverage Positive News
TVGN Tevogen Bio	2.2131 of 5 stars	$6.49 -1.7%	$100.00 +1,440.8%	-80.1%	$42.98M	N/A	N/A	18
MGX Metagenomi	4.1366 of 5 stars	$1.03 -1.0%	$6.00 +482.5%	-67.8%	$39.29M	$25.21M	N/A	113	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LTRN) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lantern Pharma (LTRN) Competitors

LTRN vs. TIL, HOWL, TVGN, MGX, and EDSA

How does Lantern Pharma compare to Instil Bio?

Summary

How does Lantern Pharma compare to Werewolf Therapeutics?

Summary

How does Lantern Pharma compare to Tevogen Bio?

Summary

How does Lantern Pharma compare to Metagenomi?

Summary

How does Lantern Pharma compare to Edesa Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lantern Pharma (LTRN) Competitors

LTRN vs. TIL, HOWL, TVGN, MGX, and EDSA

How does Lantern Pharma compare to Instil Bio?

Does the media refer more to LTRN or TIL?

Which has more volatility & risk, LTRN or TIL?

Which has stronger valuation & earnings, LTRN or TIL?

Do insiders and institutionals have more ownership in LTRN or TIL?

Is LTRN or TIL more profitable?

Do analysts rate LTRN or TIL?

Summary

How does Lantern Pharma compare to Werewolf Therapeutics?

Is HOWL or LTRN more profitable?

Which has higher valuation and earnings, HOWL or LTRN?

Which has more risk and volatility, HOWL or LTRN?

Do analysts rate HOWL or LTRN?

Do institutionals & insiders have more ownership in HOWL or LTRN?

Does the media prefer HOWL or LTRN?

Summary

How does Lantern Pharma compare to Tevogen Bio?

Does the media refer more to LTRN or TVGN?

Do institutionals and insiders have more ownership in LTRN or TVGN?

Is LTRN or TVGN more profitable?

Which has higher valuation and earnings, LTRN or TVGN?

Do analysts rate LTRN or TVGN?

Which has more risk & volatility, LTRN or TVGN?

Summary

How does Lantern Pharma compare to Metagenomi?

Do analysts prefer MGX or LTRN?

Is MGX or LTRN more profitable?

Which has stronger valuation & earnings, MGX or LTRN?

Does the media prefer MGX or LTRN?

Which has more risk & volatility, MGX or LTRN?

Do institutionals & insiders believe in MGX or LTRN?

Summary

How does Lantern Pharma compare to Edesa Biotech?

Which has more volatility and risk, LTRN or EDSA?

Which has higher valuation & earnings, LTRN or EDSA?

Is LTRN or EDSA more profitable?

Do insiders & institutionals believe in LTRN or EDSA?

Do analysts recommend LTRN or EDSA?

Does the media favor LTRN or EDSA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LTRN vs. The Competition

Lantern Pharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools